抗感染症薬市場：製品別、病原体別、作用機序別、投与経路別、エンドユーザー別-2025～2030年世界予測

抗感染症薬市場は、2023年に1,257億8,000万米ドルと評価され、2024年には1,314億3,000万米ドルに達すると予測され、CAGR 5.12％で成長し、2030年には1,784億3,000万米ドルに達すると予測されています。

抗感染症薬市場には、細菌、ウイルス、真菌、寄生虫による感染症に対処するための幅広い製品が含まれます。このカテゴリーには、抗生物質、抗ウイルス剤、抗真菌剤、抗寄生虫剤が含まれます。抗感染症薬の必要性は、感染症を治療し、病気の蔓延を防ぎ、死亡率を減少させるために不可欠であるという、医療における重要な役割にあります。これらの薬剤は、病院、外来クリニック、在宅医療の現場で使用され、ヒトと動物両方のニーズに対応しています。この市場は、小児から高齢者まで幅広い層を対象としており、製薬やバイオテクノロジーなど数多くの産業を支えています。

市場開拓の主要要因は、感染症の流行、抗菌薬耐性に対する意識の高まり、薬剤開発技術の進歩などです。特に多剤耐性病原体による新しいクラスの抗感染症薬に対するニーズの高まりは、大きなビジネス機会をもたらしています。企業は、新規治療の研究開発に投資し、バイオテクノロジー企業との提携を模索し、AI主導の創薬プロセスを活用することで、こうした展望を生かすことができます。新興国もまた、医療インフラの拡大と医療費の増加により、有利な市場を形成しています。

しかし、市場は厳しい規制や研究開発費の高騰など、新薬開発のペースを妨げるいくつかの課題に直面しています。また、市場関係者は抗菌薬耐性という複雑な問題を乗り越えなければならず、そのためには継続的な技術革新と戦略的投資が必要となります。革新のための最良の道としては、狭スペクトル薬剤の開発、併用療法、個人の遺伝子プロファイルに合わせた個別化抗感染症治療などが挙げられます。

結論として、抗感染症薬市場は広大な可能性を秘めているが、成長には規制上のハードルを克服し、コスト効率を改善し、イノベーションを促進することに戦略的に注力する必要があります。学術・研究機関との協力関係を追求することで、貴重な知見を提供し、画期的なソリューションの市場開拓を後押しすることができ、企業はこのダイナミックな市場情勢においてサステイナブル成長を遂げることができます。

市場力学：急速に進化する抗感染症薬市場における重要な市場洞察の解明

抗感染症薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また消費者行動とそれが製造コストや購買傾向に与える影響についてもより明確に理解することができます。

ポーターの5つの力：抗感染症薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗感染症薬市場における外部からの影響の把握

外部マクロ環境要因は、抗感染症薬市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析抗感染症薬市場における競合情勢の把握

抗感染症薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス抗感染症薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗感染症薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨抗感染症薬市場における成功への道筋を描く

抗感染症薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した包括的な市場分析を提供しています。

1.市場の浸透度：現在の市場環境についての詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存セクターにおける拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを調査します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行えるよう、重要な質問にも回答しています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 新興国における医療インフラの拡大が抗感染症薬市場の成長を加速
    • 効果的な抗感染薬の開発と承認を促進する厳格な規制ガイドライン
    • 抗感染薬の発見を促進するための製薬業界の戦略的協力とパートナーシップ
    • 医療費の増加と医療施設へのアクセスの向上により、抗感染症薬の需要が高まっている
  • 抑制要因
    • 抗感染薬市場における製品ライフサイクルの短さと開発コストの高さによる投資収益率の低下
    • 患者が処方された抗感染療法を遵守しないことで、治療結果が最適でなくなり、耐性が増加
  • 機会
    • 患者固有の要因に基づいた標的抗感染治療のための個別化医療アプローチの成長
    • 人工知能と機械学習を活用し、新しい抗感染化合物を迅速に特定
    • 次世代抗菌療法の開発に向けた先進バイオ調査への投資
  • 課題
    • 研究開発費の高騰により、抗感染症薬におけるイノベーションと新薬の発見が制限されている
    • 市場参入障壁が高く、中小企業が効果的に競争できない
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 抗感染症薬市場：製品別

• イントロダクション
• 生物製剤
  • インターフェロン
  • モノクローナル抗体
  • 組み換えタンパク質
• 薬剤
  • 静脈内
  • 経口液剤
  • 錠剤
• ワクチン
  • 細菌ワクチン
  • ウイルスワクチン

第7章 抗感染症薬市場：病原体別

• イントロダクション
• 細菌感染症
  • 大腸菌
  • 黄色ブドウ球菌
• 真菌感染症
  • アスペルギルス
  • カンジダ
• 寄生虫感染症
  • リーシュマニア症
  • マラリア
• ウイルス感染
  • 肝炎
  • HIV

第8章 抗感染症薬市場：作用機序別

• イントロダクション
• 細胞壁合成阻害剤
• 核酸合成阻害剤
• タンパク質合成阻害剤

第9章 抗感染症薬市場：投与経路別

• イントロダクション
• 静脈内
• 経口
• 局所

第10章 抗感染症薬市場：エンドユーザー別

• イントロダクション
• クリニック
• 在宅医療
• 病院

第11章 南北アメリカの抗感染症薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の抗感染症薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの抗感染症薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. AbbVie Inc.
• 2. Allergan plc
• 3. Amgen Inc.
• 4. Astellas Pharma Inc.
• 5. AstraZeneca PLC
• 6. Bayer AG
• 7. Bristol-Myers Squibb Company
• 8. Cubist Pharmaceuticals, Inc.
• 9. Eli Lilly and Company
• 10. F. Hoffmann-La Roche AG
• 11. Gilead Sciences, Inc.
• 12. GlaxoSmithKline plc
• 13. Johnson & Johnson
• 14. Merck & Co., Inc.
• 15. Novartis AG
• 16. Pfizer Inc.
• 17. Sanofi S.A.
• 18. Shionogi & Co., Ltd.
• 19. Takeda Pharmaceutical Company Limited
• 20. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

• FIGURE 1. ANTI-INFECTIVES MARKET RESEARCH PROCESS
• FIGURE 2. ANTI-INFECTIVES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. ANTI-INFECTIVES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. ANTI-INFECTIVES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTI-INFECTIVES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTI-INFECTIVES MARKET DYNAMICS
• TABLE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL LIQUIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VIRAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ASPERGILLUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CANDIDA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MALARIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CELL WALL SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEIC ACID SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 70. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 71. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 72. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 73. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 74. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 80. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 81. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 82. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 83. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 84. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 85. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 86. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. CANADA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. CANADA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 90. CANADA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 91. CANADA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 92. CANADA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 93. CANADA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 94. CANADA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 95. CANADA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 96. CANADA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 97. CANADA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 98. CANADA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. CANADA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. MEXICO ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. MEXICO ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 102. MEXICO ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 103. MEXICO ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 104. MEXICO ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 105. MEXICO ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 106. MEXICO ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 107. MEXICO ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 108. MEXICO ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 109. MEXICO ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 110. MEXICO ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. MEXICO ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 114. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 115. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 116. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 117. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 118. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 119. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 120. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 121. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 122. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 127. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 128. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 129. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 130. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 131. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 132. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 133. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 134. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 135. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 138. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 139. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 140. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 141. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 142. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 143. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 144. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 145. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 146. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 147. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 148. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. CHINA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. CHINA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 152. CHINA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 153. CHINA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 154. CHINA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 155. CHINA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 156. CHINA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 157. CHINA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 158. CHINA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 159. CHINA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 160. CHINA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 161. CHINA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. INDIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 163. INDIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 164. INDIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 165. INDIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 166. INDIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 167. INDIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 168. INDIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 169. INDIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 170. INDIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 171. INDIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 172. INDIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. INDIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 174. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 175. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 176. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 177. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 178. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 179. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 180. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 181. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 182. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 183. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 184. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. JAPAN ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. JAPAN ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 188. JAPAN ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 189. JAPAN ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 190. JAPAN ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 191. JAPAN ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 192. JAPAN ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 193. JAPAN ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 194. JAPAN ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 195. JAPAN ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 196. JAPAN ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 197. JAPAN ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 198. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 199. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 200. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 201. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 202. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 203. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 204. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 205. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 206. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 207. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 208. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 209. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 210. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 211. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 212. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 213. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 214. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 215. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 216. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 217. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 218. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 219. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 220. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 221. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 222. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 223. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 224. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 225. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 226. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 227. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 228. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 229. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 230. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 231. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 232. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 233. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 234. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 235. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 236. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 237. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 238. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 246. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 247. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 248. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 249. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 250. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 251. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 252. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 253. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 254. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 255. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 256. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 257. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 258. THAILAND ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 259. THAILAND ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 260. THAILAND ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 261. THAILAND ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 262. THAILAND ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 263. THAILAND ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 264. THAILAND ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 265. THAILAND ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 266. THAILAND ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 267. THAILAND ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 268. THAILAND ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 269. THAILAND ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 270. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 271. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 272. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 273. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 274. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 275. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 276. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 277. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 278. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 279. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 280. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 281. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 283. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 284. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 285. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 286. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 287. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 288. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 289. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 290. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 291. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 292. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 293. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 294. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 295. DENMARK ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 296. DENMARK ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 297. DENMARK ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 298. DENMARK ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 299. DENMARK ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 300. DENMARK ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 301. DENMARK ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 302. DENMARK ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 303. DENMARK ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 304. DENMARK ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 305. DENMARK ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 306. DENMARK ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 307. EGYPT ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 308. EGYPT ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 309. EGYPT ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 310. EGYPT ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 311. EGYPT ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 312. EGYPT ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 313. EGYPT ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 314. EGYPT ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 315. EGYPT ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 316. EGYPT ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 317. EGYPT ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 318. EGYPT ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 319. FINLAND ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 320. FINLAND ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 321. FINLAND ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 322. FINLAND ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 323. FINLAND ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 324. FINLAND ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 325. FINLAND ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 326. FINLAND ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 327. FINLAND ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 328. FINLAND ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 329. FINLAND ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 330. FINLAND ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 331. FRANCE ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 332. FRANCE ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 333. FRANCE ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 334. FRANCE ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 335. FRANCE ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 336. FRANCE ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 337. FRANCE ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 338. FRANCE ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 339. FRANCE ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 340. FRANCE ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 341. FRANCE ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 342. FRANCE ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 343. GERMANY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 344. GERMANY ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 345. GERMANY ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 346. GERMANY ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
• TABLE 347. GERMANY ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 348. GERMANY ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 349. GERMANY ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 350. GERMANY ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 351. GERMANY ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 352. GERMANY ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 353. GERMANY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 354. GERMANY ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 355. ISRAEL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 356. ISRAEL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 357. ISRAEL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 358. ISRAEL

The Anti-infectives Market was valued at USD 125.78 billion in 2023, expected to reach USD 131.43 billion in 2024, and is projected to grow at a CAGR of 5.12%, to USD 178.43 billion by 2030.

The anti-infectives market encompasses a broad range of products designed to combat infections caused by bacteria, viruses, fungi, and parasites. This category includes antibiotics, antivirals, antifungals, and antiparasitic agents. The necessity of anti-infectives lies in their critical role in healthcare, as they are essential for treating infections, preventing disease spread, and reducing mortality. These agents find applications in hospitals, outpatient clinics, and home healthcare settings, catering to both human and veterinary needs. The market serves a wide demographic, from pediatric to geriatric populations, and supports numerous industries, including pharmaceuticals and biotechnology.

Market growth is primarily driven by factors such as the increasing prevalence of infectious diseases, growing awareness of antimicrobial resistance, and advances in drug development technologies. The rising need for new classes of anti-infectives, especially due to multidrug-resistant pathogens, presents significant opportunities. Companies can capitalize on these prospects by investing in R&D for novel therapeutics, exploring partnerships with biotechnology firms, and leveraging AI-driven drug discovery processes. Emerging economies also present lucrative markets due to their expanding healthcare infrastructure and rising healthcare expenditure.

However, the market faces several challenges, including stringent regulatory mandates and the high cost of R&D, which can hinder the pace of new drug development. Market players must also navigate the complexities of antimicrobial resistance, which requires continuous innovation and strategic investment. The best avenues for innovation include development of narrow-spectrum agents, combination therapies, and personalized anti-infective treatments tailored to individual genetic profiles.

In conclusion, while the anti-infectives market holds expansive potential, growth demands strategic focus on overcoming regulatory hurdles, improving cost efficiency, and fostering innovation. Pursuing collaborations with academic and research institutions can provide valuable insights and boost the development of groundbreaking solutions, positioning companies for sustainable growth in this dynamic market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-infectives Market

The Anti-infectives Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Expansion of healthcare infrastructure in emerging economies fueling the anti-infectives market growth
  • Stringent regulatory guidelines promoting the development and approval of effective anti-infective medications
  • The pharmaceutical industry's strategic collaborations and partnerships to boost anti-infective drug discovery
  • Increasing healthcare expenditure and better access to medical facilities driving demand for anti-infectives
• Market Restraints
  • Lower return on investment due to short product lifecycles and high cost of development in anti-infective market
  • Patient non-adherence to prescribed anti-infective regimens leading to suboptimal treatment outcomes and increased resistance
• Market Opportunities
  • Growth of personalized medicine approaches for targeted anti-infective treatments based on patient-specific factors
  • Leveraging artificial intelligence and machine learning for rapid identification of novel anti-infective compounds
  • Investing in advanced biotechnological research for development of next-generation anti-microbial therapies
• Market Challenges
  • Escalating research and development costs limiting innovation and new drug discoveries in anti-infectives
  • High market entry barriers preventing small and medium-sized enterprises from competing effectively

Porter's Five Forces: A Strategic Tool for Navigating the Anti-infectives Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-infectives Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-infectives Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-infectives Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-infectives Market

A detailed market share analysis in the Anti-infectives Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-infectives Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-infectives Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-infectives Market

A strategic analysis of the Anti-infectives Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-infectives Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Shionogi & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Anti-infectives Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Biologics, Drugs, and Vaccines. The Biologics is further studied across Interferons, Monoclonal Antibodies, and Recombinant Proteins. The Drugs is further studied across Intravenous, Oral Liquids, and Tablets. The Vaccines is further studied across Bacterial Vaccines and Viral Vaccines.
• Based on Pathogen, market is studied across Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections. The Bacterial Infections is further studied across Escherichia Coli and Staphylococcus Aureus. The Fungal Infections is further studied across Aspergillus and Candida. The Parasitic Infections is further studied across Leishmaniasis and Malaria. The Viral Infections is further studied across Hepatitis and HIV.
• Based on Mechanism Of Action, market is studied across Cell Wall Synthesis Inhibitors, Nucleic Acid Synthesis Inhibitors, and Protein Synthesis Inhibitors.
• Based on Route Of Administration, market is studied across Intravenous, Oral, and Topical.
• Based on End User, market is studied across Clinics, Homecare, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Expansion of healthcare infrastructure in emerging economies fueling the anti-infectives market growth
    • 5.1.1.2. Stringent regulatory guidelines promoting the development and approval of effective anti-infective medications
    • 5.1.1.3. The pharmaceutical industry's strategic collaborations and partnerships to boost anti-infective drug discovery
    • 5.1.1.4. Increasing healthcare expenditure and better access to medical facilities driving demand for anti-infectives
  • 5.1.2. Restraints
    • 5.1.2.1. Lower return on investment due to short product lifecycles and high cost of development in anti-infective market
    • 5.1.2.2. Patient non-adherence to prescribed anti-infective regimens leading to suboptimal treatment outcomes and increased resistance
  • 5.1.3. Opportunities
    • 5.1.3.1. Growth of personalized medicine approaches for targeted anti-infective treatments based on patient-specific factors
    • 5.1.3.2. Leveraging artificial intelligence and machine learning for rapid identification of novel anti-infective compounds
    • 5.1.3.3. Investing in advanced biotechnological research for development of next-generation anti-microbial therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Escalating research and development costs limiting innovation and new drug discoveries in anti-infectives
    • 5.1.4.2. High market entry barriers preventing small and medium-sized enterprises from competing effectively
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-infectives Market, by Product

• 6.1. Introduction
• 6.2. Biologics
  • 6.2.1. Interferons
  • 6.2.2. Monoclonal Antibodies
  • 6.2.3. Recombinant Proteins
• 6.3. Drugs
  • 6.3.1. Intravenous
  • 6.3.2. Oral Liquids
  • 6.3.3. Tablets
• 6.4. Vaccines
  • 6.4.1. Bacterial Vaccines
  • 6.4.2. Viral Vaccines

7. Anti-infectives Market, by Pathogen

• 7.1. Introduction
• 7.2. Bacterial Infections
  • 7.2.1. Escherichia Coli
  • 7.2.2. Staphylococcus Aureus
• 7.3. Fungal Infections
  • 7.3.1. Aspergillus
  • 7.3.2. Candida
• 7.4. Parasitic Infections
  • 7.4.1. Leishmaniasis
  • 7.4.2. Malaria
• 7.5. Viral Infections
  • 7.5.1. Hepatitis
  • 7.5.2. HIV

8. Anti-infectives Market, by Mechanism Of Action

• 8.1. Introduction
• 8.2. Cell Wall Synthesis Inhibitors
• 8.3. Nucleic Acid Synthesis Inhibitors
• 8.4. Protein Synthesis Inhibitors

9. Anti-infectives Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Intravenous
• 9.3. Oral
• 9.4. Topical

10. Anti-infectives Market, by End User

• 10.1. Introduction
• 10.2. Clinics
• 10.3. Homecare
• 10.4. Hospitals

11. Americas Anti-infectives Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Anti-infectives Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Anti-infectives Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Allergan plc
• 3. Amgen Inc.
• 4. Astellas Pharma Inc.
• 5. AstraZeneca PLC
• 6. Bayer AG
• 7. Bristol-Myers Squibb Company
• 8. Cubist Pharmaceuticals, Inc.
• 9. Eli Lilly and Company
• 10. F. Hoffmann-La Roche AG
• 11. Gilead Sciences, Inc.
• 12. GlaxoSmithKline plc
• 13. Johnson & Johnson
• 14. Merck & Co., Inc.
• 15. Novartis AG
• 16. Pfizer Inc.
• 17. Sanofi S.A.
• 18. Shionogi & Co., Ltd.
• 19. Takeda Pharmaceutical Company Limited
• 20. Vertex Pharmaceuticals Incorporated